Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02366611
Other study ID # HUM 78942
Secondary ID U036889
Status Completed
Phase N/A
First received
Last updated
Start date November 2014
Est. completion date November 2019

Study information

Verified date January 2021
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if Transcranial Direct Current Stimulation (tDCS) can reduce pain perception associated with the effects of receiving definitive radiation therapy or chemoradiotherapy in head and neck cancer (HNCa) patients.


Description:

The goal of this study is to investigate the effectiveness of tDCS as a novel pain relief modality for odynophagia due to mucositis in patients with locally advanced head and neck cancer undergoing definitive radiation therapy or chemoradiotherapy. Participants will be randomized into one of two arms: (1) Treatment: radiation/chemoradiotherapy standard of care + tDCS neuromodulation or (2) Control: radiation/chemoradiotherapy standard of care only. Patients in the treatment arm will undergo tDCS stimulation on the day of their radiation/chemoradiotherapy appointments, prior to receiving treatment when doing tDCS session in clinic or after to receiving treatment when doing tDCS session at home. This will occur daily (5 days per week) during the second and third weeks of therapy, three times per week during the fourth and fifth weeks, and twice per week during the sixth and seventh weeks. Patients will also have EEG and fNIRS recordings during the study. This will occur at the pre-study visit, the first stimulation appointment, the third week, the 7th week, and during the follow-up appointments (one-week and one-month).


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date November 2019
Est. primary completion date November 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients with AJCC stage III-IV head and neck malignancy scheduled for definitive radiation therapy or chemoradiotherapy, and who are capable of understanding and adhering to the protocol requirements. Exclusion Criteria: - Substantial dementia - Patients are actively being treated for another cancer at the time of enrollment. - Any condition that would prevent use of tDCS including skull abnormality, implanted metal, implanted electronic device, seizure disorder, neurologic condition. - Use of an investigational drug or device within 30 days of study screening

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial Direct Current Stimulation (tDCS)
tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analog Scale (VAS) A Visual Analog Scale (VAS) will be used to assess patient-reported odynophagia at weekly Radiation Oncology on-treatment visits (OTVs). The VAS is a traditional pain assessment tool that has been used and validated widely in both clinical and research settings, including studies of oral mucositis pain. This scale ranges from 0-100, in which 0 means no odynophagia, and 100 means highest level of odynophagia ever. Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)
Primary EEG Power Spectrum Week1/Week7 EEG data power spectrum analysis. Week1 and Week 7 difference. Note: the control participant's data was not reported due to limited number of participant in the control group. The report was divided into five frequency bands:
Delta = 0-4 Hz
Theta = 4-7 Hz
Alpha = 8-15 Hz
Beta= 16-31 Hz
Gamma 32-50 Hz
The data was recorded at P3, Fz, Cz, F3, Fp1, Fp2 points in the international 10-20 system.
The analysis was done using EEGLab V 14.1.1.
Week1/Week7
Primary EEG Spectrum Pre-Post tDCS Session EEG data power spectrum analysis. Pre/Post-tDCS session. The report was divided into five frequency bands:
Delta = 0-4 Hz
Theta = 4-7 Hz
Alpha = 8-15 Hz
Beta= 16-31 Hz
Gamma 32-50 Hz
The data was recorded at P3, Fz, Cz, F3, Fp1, Fp2 points in the international 10-20 system.
Note: the control participant's data was not reported due to limited number of participant in the control group.
Pre/Post-tDCS Session
Secondary Oral-Mucositis Weekly Evaluation - Overall 1-7 scale grading self-evaluated overall physical condition, 7= Excellent, 1 = Very poor. Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)
Secondary Patient Weight Participant's weight each measurement time point. Note: 0 means data missing. Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)
Secondary Positive and Negative Affect Schedule The General Positive and General Negative scores in the PANAS forms are reported for both pre- and post- treatment. The General Positive (GP) and General Negative (GN) scores were reported. Each score ranges from 10-50, in which 10 = lowest (positive/negative emotional level) and 50 = highest (positive/negative emotional level). Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)
Secondary Washington Quality Of Life Questionnaire The Washington Quality Of Life questionnaire (QOL) is one of the most frequently reported health-related QOL questionnaires in head and neck cancer. This questionnaire scaled from 0 (worst) to 100 (best) according to the hierarchy of response. Pre-treatment (baseline), Week 7 of treatment, 1 week and 1 month follow-ups (post-treatment)
Secondary Present Pain Intensity Index in McGill Questionnaire Pre-tDCS Treatment The Present Pain Intensity (PPI) index is recorded as a number ranges from 0 to 5, in which each number is associated with the following words: 0 no pain, 1 mild, 2 discomforting, 3 distressing, 4 horrible, 5 excruciating. Pre-treatment (baseline), throughout treatment (once a week for 7 weeks), 1 week and 1 month follow-ups (post-treatment)
See also
  Status Clinical Trial Phase
Withdrawn NCT05331131 - Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial Phase 2
Completed NCT05269342 - Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer N/A
Completed NCT03574870 - Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer N/A
Recruiting NCT04804852 - Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer
Active, not recruiting NCT04617678 - A Comprehensive Approach to Head and Neck Cancer Prehabilitation N/A
Completed NCT03419741 - Brain Stimulation For Cancer Smokers N/A
Recruiting NCT02528955 - De-Intensification Radiotherapy Postoperative Head Neck Phase 2
Completed NCT00318890 - Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck Phase 1/Phase 2
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting NCT05316974 - Lymphoedema Among Persons With Head- and Neck Cancer
Not yet recruiting NCT03954691 - Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
Active, not recruiting NCT03760471 - Palliative and Oncology Care Intervention: Symptom COACH N/A
Completed NCT04554667 - Heavy Lifting Strength Training in Head and Neck Cancer Survivors Phase 1
Completed NCT02869399 - Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention N/A
Completed NCT02075112 - Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck Phase 1
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT02900911 - Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy N/A
Completed NCT01317589 - Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective? Phase 4
Completed NCT03841175 - Forecasts Impact of the Pre-therapeutic TEP-TDM in the 18-FDG Restaging of Upper Aero-digestive Tract Cancers
Completed NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Phase 1/Phase 2